UBRELVY Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ubrelvy, and when can generic versions of Ubrelvy launch?
Ubrelvy is a drug marketed by Allergan and is included in one NDA. There are five patents protecting this drug.
This drug has eighty-eight patent family members in forty-one countries.
The generic ingredient in UBRELVY is ubrogepant. One supplier is listed for this compound. Additional details are available on the ubrogepant profile page.
DrugPatentWatch® Generic Entry Outlook for Ubrelvy
Ubrelvy will be eligible for patent challenges on December 23, 2023. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be January 30, 2035. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for UBRELVY
International Patents: | 88 |
US Patents: | 5 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 20 |
Clinical Trials: | 5 |
Patent Applications: | 73 |
Drug Prices: | Drug price information for UBRELVY |
What excipients (inactive ingredients) are in UBRELVY? | UBRELVY excipients list |
DailyMed Link: | UBRELVY at DailyMed |


DrugPatentWatch® Estimated Generic Entry Opportunity Date for UBRELVY
Generic Entry Date for UBRELVY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for UBRELVY
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Allergan | Phase 4 |
Messoud Ashina, MD | Phase 4 |
Allergan | Phase 3 |
Anatomical Therapeutic Chemical (ATC) Classes for UBRELVY
US Patents and Regulatory Information for UBRELVY
UBRELVY is protected by five US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of UBRELVY is See Plans and Pricing.
This potential generic entry date is based on patent See Plans and Pricing.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting UBRELVY
Tablet formulation for CGRP active compounds
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH HEADACHE, WITH OR WITHOUT AURA IN ADULTS
Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
Piperidinone carboxamide azaindane CGRP receptor antagonists
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS
FDA Regulatory Exclusivity protecting UBRELVY
NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-002 | Dec 23, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-001 | Dec 23, 2019 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
Allergan | UBRELVY | ubrogepant | TABLET;ORAL | 211765-002 | Dec 23, 2019 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for UBRELVY
When does loss-of-exclusivity occur for UBRELVY?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 15214502
Estimated Expiration: See Plans and Pricing
Patent: 19226239
Estimated Expiration: See Plans and Pricing
Patent: 21245229
Estimated Expiration: See Plans and Pricing
Canada
Patent: 37315
Estimated Expiration: See Plans and Pricing
Patent: 37942
Estimated Expiration: See Plans and Pricing
China
Patent: 5939715
Estimated Expiration: See Plans and Pricing
Patent: 5960397
Estimated Expiration: See Plans and Pricing
Patent: 2022818
Estimated Expiration: See Plans and Pricing
European Patent Office
Patent: 02188
Estimated Expiration: See Plans and Pricing
Patent: 02210
Estimated Expiration: See Plans and Pricing
Patent: 02211
Estimated Expiration: See Plans and Pricing
Patent: 02564
Estimated Expiration: See Plans and Pricing
Patent: 37412
Estimated Expiration: See Plans and Pricing
Hong Kong
Patent: 32218
Estimated Expiration: See Plans and Pricing
Israel
Patent: 6828
Estimated Expiration: See Plans and Pricing
Japan
Patent: 91669
Estimated Expiration: See Plans and Pricing
Patent: 66490
Estimated Expiration: See Plans and Pricing
Patent: 17505306
Estimated Expiration: See Plans and Pricing
Patent: 19108366
Estimated Expiration: See Plans and Pricing
Mexico
Patent: 16010169
Estimated Expiration: See Plans and Pricing
Russian Federation
Patent: 96578
Estimated Expiration: See Plans and Pricing
Patent: 19123406
Estimated Expiration: See Plans and Pricing
Saudi Arabia
Patent: 6371613
Estimated Expiration: See Plans and Pricing
South Korea
Patent: 160113296
Estimated Expiration: See Plans and Pricing
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering UBRELVY around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2937942 | COMBINAISONS A DOSE FIXE DE COMPOSES ANTIVIRAUX (FIXED-DOSE COMBINATIONS OF ANTIVIRAL COMPOUNDS) | See Plans and Pricing |
Saudi Arabia | 516371613 | CGRP صيغة قرص لمركبات نشطة تجاه (Tablet Formulation for CGRP-Active Compounds) | See Plans and Pricing |
World Intellectual Property Organization (WIPO) | 2015119919 | See Plans and Pricing | |
Poland | 2821407 | See Plans and Pricing | |
>Country | >Patent Number | >Title | >Estimated Expiration |